Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Summary

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works as first-line therapy in treating patients with gastrointestinal stromal tumors.

Timeline

Start

2008-01-22

Primary completion

2012-01-18

Completion

2018-05-16

Drugs

Indications